Boehringer Ingelheim International GmbH

Boehringer Ingelheim International GmbH

CNS Disease Research
Birkendorfer Strasse 65
88397 Biberach
GERMANY

https://www.boehringer-ingelheim.de/

Dr. Hugh Marston, F.R.S.B.
Dr. Hugh Marston, F.R.S.B.

Senior Vice President & Head of Global CNS Disease Research


Send E-Mail
Prof. Dr. Bastian Hengerer
Prof. Dr. Bastian Hengerer

Director CNS Diseases Research


Send E-Mail
Dr. Vikas Sharma
Dr. Vikas Sharma

Global Head Medicine CNS


Send E-Mail

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

At Boehringer Ingelheim Mental Health, we are redefining mental health to enable people to thrive. We link behavior to the underlying neurobiology to develop targeted therapies that can ease the burden of these conditions, not just the symptoms. By combining traditional treatment approaches with new and innovative approaches and technologies, we will enable those with mental health conditions to create more meaningful connections to their lives, loved ones and society.

We are the project leader of PRISM 2 and therefore actively involved in all work packages, especially WP1 (project management & governance). Together with the project coordinator, we oversee the progress of all work packages.

Follow us on social media:
Facebook Twitter